Editorial: Hot flashes and hormone use: Harbingers of heart disease?

Menopause

Volumn 17, Issue 2, 2010, Pages 223-225

  Brinton, Eliot A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; BRACHIAL ARTERY; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; HEART DISEASE; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MENSTRUATION; PREMENOPAUSE; STROKE; VASODILATATION; VASOMOTOR DISORDER; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; MENOPAUSE; NOTE; WOMEN'S HEALTH;

CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; WOMEN'S HEALTH;

EID: 77949348048     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181d297b9     Document Type: Editorial

References (21)

1. Danby FW. Management of menopause-related symptoms. Ann Intern Med 2005;143:845-846; author reply 6.
2. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
3. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365.
4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) research group. JAMA 1998;280:605-613.
5. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
6. Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause 2009;16:639-643.
7. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 2008;118:1234-1240.
8. Thurston RC, Kuller L, Edmundowicz D, Matthews KA. History of hot flashes and aortic calcification among postmenopausal women. Menopause 2010;17:256-261.
9. Allison MA, Manson JE. The complex interplay of vasomotor symptoms, hormone therapy, and cardiovascular risk. Menopause 2009;16: 619-620.
10. Budoff MJ, Chen GP, Hunter CJ, et al. Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. J Womens Health (Larchmt) 2005;14:410-417.
11. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602.
12. Allison MA, Manson JE, Langer RD, et al. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause 2008;15:639-647.
13. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115:455-456.
14. Brinton EA, Hodis HN, Merriam GR, Harman SM, Naftolin F. Can menopausal hormone therapy prevent coronary heart disease? Trends Endocrinol Metab 2008;19:206-212.
15. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
16. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804.
17. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-366.
18. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44.
19. Gupta P, Harte AL, da Silva NF, et al. Expression of calcitonin gene-related peptide, adrenomedullin, and receptor modifying proteins in human adipose tissue and alteration in their expression with menopause status. Menopause 2007;14:1031-1038.
20. Gupta P, Harte A, Sturdee DW, et al. Effects of menopausal status on circulating calcitonin gene-related peptide and adipokines: implications for insulin resistance and cardiovascular risks. Climacteric 2008;11:364-372.
21. US Food and Drug Administration. FDA updates hormone therapy information for postmenopausal women 2004. Available at: http://www.fda. gov/bbs/topics/NEWS/2004/NEW01022.html. Accessed January 4, 2006.